Connect Biopharma Holdings Ltd (CNTB) Implied Volatility Current

Tracking CNTB implied volatility helps you identify when options premiums on Connect Biopharma Holdings Ltd are historically cheap or expensive, and where the best trades are hiding. Connect Biopharma Holdings Ltd implied volatility reflects the market's expectation of future price movement: when CNTB IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Connect Biopharma Holdings Ltd's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For CNTB, tracking metrics like CNTB IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on CNTB signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation.

The company was founded in 2012 and is headquartered in Taicang, China.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where CNTB implied volatility sits today versus where it has been. Our scanner ranks Connect Biopharma Holdings Ltd implied volatility against its historical range, surfaces extremes in CNTB IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Connect Biopharma Holdings Ltd IV is rich or cheap — measure it, then act on it.